You are using an outdated browser. Please upgrade your browser to improve your experience.

Tclin
ERBB2
Receptor tyrosine-protein kinase erbB-2

Protein Summary
Description
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and S ...more
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000269571
  • ENSP00000269571
  • ENSG00000141736
  • ENST00000406381
  • ENSP00000385185
  • ENST00000541774
  • ENSP00000446466
  • ENST00000584601
  • ENSP00000462438

Symbol
  • HER2
  • MLN19
  • NEU
  • NGL
  • NEU
  • NGL
  • HER2
  • TKR1
  • CD340
  • HER-2
  • MLN 19
  • HER-2/neu
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
biological process
1
biological term
1
hub protein
1
molecular function
1
protein domain
1


IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 23454.08   (req: < 5)
Gene RIFs: 2521   (req: <= 3)
Antibodies: 5131   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 23454.08   (req: >= 5)
Gene RIFs: 2521   (req: > 3)
Antibodies: 5131   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 54
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 374
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 11
Approved Drugs (11)
1 – 10 of 11
ibrutinib
chemical structure image
lapatinib
chemical structure image
neratinib
chemical structure image
afatinib
chemical structure image
acalabrutinib
chemical structure image
dacomitinib
chemical structure image
trastuzumab emtansine
no chemical structure image available
trastuzumab deruxtecan
no chemical structure image available
tucatinib
chemical structure image
pertuzumab
no chemical structure image available
Protein Data Bank (31)
1 – 5 of 31
PDB Structure Id
Ligand
Method
Resolution (Å)
M.W. (kDa)
Pub Year
Title
PDB Structure Id
M.W.
Resolution
Pub Year
Pathways (94)
Axon guidance (R-HSA-422475)

Click on a row in the table to change the structure displayed.

Items per page:
1 – 5 of 40
Data Source
Name
Explore in Pharos
Explore in Source
Reactome
Axon guidance
Reactome
Constitutive Signaling by Aberrant PI3K in Cancer
Reactome
Cytokine Signaling in Immune system
Reactome
Developmental Biology
Reactome
Disease
Name
Explore in Pharos
Explore in Source
Axon guidance
Constitutive Signaling by Aberrant PI3K in Cancer
Cytokine Signaling in Immune system
Developmental Biology
Disease
Gene Ontology Terms (67)
Items per page:
10
1 – 10 of 13
GO Term
Evidence
Assigned by
Inferred from Direct Assay (IDA)
UniProtKB
Inferred from Direct Assay (IDA)
BHF-UCL
Inferred from Direct Assay (IDA)
UniProtKB
Inferred from Direct Assay (IDA)
BHF-UCL
Inferred from Direct Assay (IDA)
BHF-UCL
Inferred from Physical Interaction (IPI)
IntAct
Inferred from Physical Interaction (IPI)
UniProtKB
Inferred from Physical Interaction (IPI)
UniProtKB
Traceable Author Statement (TAS)
ProtInc
Traceable Author Statement (TAS)
Reactome
Protein-Protein Interactions (690)
1 – 10 of 690
CD79B
Tclin
Novelty: 0.00265318
p_int: 0.993757296
p_ni: 0.006242702
p_wrong: 1e-9
Score: 0.237
Data Source: BioPlex,STRINGDB
NAALADL2
Tbio
Family: Enzyme
Novelty: 0.32249808
p_int: 0.936910274
p_ni: 0.063089726
Score: 0.373
Data Source: BioPlex,STRINGDB
TGFBR2
Tchem
Family: Kinase
Novelty: 0.00128741
p_int: 0.88394082
p_ni: 0.11605918
Score: 0.379
Data Source: BioPlex,STRINGDB
DTWD2
Tdark
Novelty: 2.30769231
p_int: 0.880411283
p_ni: 0.119588717
Score: 0.221
Data Source: BioPlex,STRINGDB
MAS1
Tchem
Family: GPCR
Novelty: 0.00884994
p_int: 0.801578481
p_ni: 0.198421518
p_wrong: 1e-9
Score: 0.179
Data Source: BioPlex,STRINGDB
STK36
Tdark
Family: Kinase
Novelty: 0.30550841
p_int: 0.796815033
p_ni: 0.203184967
Data Source: BioPlex
PTGER3
Tclin
Family: GPCR
Novelty: 0.00155764
p_int: 0.790933678
p_ni: 0.209066321
p_wrong: 1e-9
Score: 0.265
Data Source: BioPlex,STRINGDB
HAVCR2
Tbio
Novelty: 0.00217571
p_int: 0.783664344
p_ni: 0.216335656
Score: 0.344
Data Source: BioPlex,STRINGDB
IL4R
Tclin
Novelty: 0.00547841
p_int: 0.768729154
p_ni: 0.231270846
Score: 0.271
Data Source: BioPlex,STRINGDB
EGF
Tbio
Novelty: 0.00015623
Score: 0.996
Data Source: Reactome,STRINGDB
Publication Statistics
PubMed Score  23454.08

PubMed score by year
PubTator Score  19665.93

PubTator score by year
Patents
Amino Acid Sequence
Residue Counts
Sequence
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNAS
1-70
LSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLREL
70-140
QLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSE
140-210
DCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFE
210-280
SMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHL
280-350
REVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
350-420
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPH
420-490
QALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHC
490-560
LPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINC
560-630
THSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPL
630-700
TPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDE
700-770
AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
770-840
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGV
840-910
TVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMA
910-980
RDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSS
980-1050
STRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPL
1050-1120
PSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGA
1120-1190
VENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
1190-1255
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV